Erectile dysfunction (ED) is frequent in patients with essential hypertension (EH); a likely common pathogenetic pathway could be a reduced ability of arteriolar vascular smooth muscle (VSM) to relax. Increasing intracellular levels of cGMP reduce the contractile status of VSM; on the contrary, type 5 cGMP-specific phosphodiesterase (PDE5, codified by PDE5A gene) regulates cGMP levels through its clearance. The PDE5A gene represents a good candidate for the intermediate phenotype EH/ED: genetic variants of the PDE5A may predispose to EH and ED and could affect the local and systemic response to sildenafil administration. Thus, a functionally relevant portion of PDE5 5 0 -flanking promoter region was analyzed by PCR and direct sequencing in patients with EH and idiopathic ED. The sequences obtained showed a T/G polymorphism at position -1142, near an AP1 regulatory element, that was not apparently associated with the intermediate phenotype. We also studied the relationship between this polymorphism and the effects of oral sildenafil on blood pressure (BP) and heart rate (HR) in men with ED. Sildenafil caused a significant decrease of BP, but had no effects on HR; statistical analysis showed no differences in BP and HR variations among PDE5A genotypes. In conclusion, our data showed no correlations of a novel polymorphism of the PDE5A promoter gene with the intermediate phenotype EH/ED and the BP and HR response to sildenafil administration. Further studies are necessary to define the role of this polymorphism and to study the genetic predisposition for EH with ED.
Introduction
Erectile dysfunction (ED) is frequent in patients with essential hypertension (EH) independent of pharmacological therapy and/or accelerated atherosclerosis. [1] [2] [3] [4] [5] Many common risk factors are involved in both ED and EH (eg age, diabetes, dyslipidemia, obesity), but it is not clear if a common mechanism could be responsible for the association between EH and ED. [6] [7] [8] A likely common pathogenetic pathway could be a reduced ability of arteriolar vascular smooth muscle (VSM) to relax. 9, 10 One of the main regulators of VSM contractile tone is cGMP: 11 increasing intracellular levels of cGMP reduce the contractile status of VSM and induce vasodilation with systemic and local effects (eg blood pressure (BP) decrease, erection). 12, 13 Whereas cGMP synthesis is stimulated by natriuretic peptides and nitric oxide (NO), its clearance is regulated, at least in part, by type 5 cGMPspecific phosphodiesterase (PDE5). 14 Sildenafil, a PDE5 inhibitor used in ED, [15] [16] [17] also induces a small, transient, systemic decrease of BP, which may be symptomatic and severe in the presence of stimulated cGMP synthesis by nitrate therapy. 18, 19 Thus, the PDE5A gene, which codes for PDE5, represents a good candidate for the intermediate phenotype EH/ED: genetic variants in the PDE5A gene may predispose to EH and ED. Moreover, PDE5A alleles could determine different effects of oral sildenafil administration on BP, heart rate (HR) and erectile function.
Many candidate genes for hypertension have their clinically relevant polymorphisms in the 5 0 -flanking regulatory region. [20] [21] [22] The regulatory region of the PDE5A gene was described 23 (GenBank accession no. AB001615) and showed several potential regulatory factor-binding sequences. 23 Among these regulatory sequences, there are two AP1 elements located at positions -1302 and -1204 (AB001615): these elements, known to mediate cGMP signal transduction pathway, 24 are likely to be the most important positive regulators of PDE5A gene expression and, moreover, cGMP may be not only a common mediator of penile and systemic arterial vasodilatation, but, at the genomic level, also a common regulator of genes involved in EH/ED phenotype.
The aim of our study was to analyze the sequences around the nearest AP1 transcriptional regulatory element in the 5 0 -flanking region of PDE5A gene in patients with both EH and idiopathic ED to find genetic variants and, then, to test their association with EH and ED.
Materials and methods

Populations of the study
In a first step of the study, we selected 10 consecutive patients without diabetes (age p60 y; mean 5674) affected by idiopathic ED and EH, afferent to the Department of Urology. Exclusion of secondary forms of ED was performed by anamnesis, psychiatric evaluation, Rigiscan, biothesiometry and cavernous body's Doppler flussimetry (basal and after intracavernous injection of PGE 2 ). Exclusion of secondary forms of hypertension was performed by clinical and laboratory evaluation; hypertension was defined as BP X140 and/or X90 mmHg or treatment with antihypertensive drugs. After obtaining informed consent, blood was drawn for genomic DNA extraction, amplification and direct sequencing.
In a second step, we recruited 83 consecutive male patients affected by EH afferent to the Department of Internal Medicine, with positive family history for hypertension (at least one first-degree relative affected); they were evaluated for the presence/absence of ED by medical interview, excluding diabetic patients, patients taking antihypertensive drugs that could cause ED (diuretics, bblockers, a 2 -agonists), and patients with peripheral vascular diseases. Blood was drawn for genomic DNA extraction and genotyping.
In a third step, we further recruited 21 patients with idiopathic ED (age 30-70 y), who, after andrologic and cardiologic evaluation (when clinically indicated), were candidates for oral sildenafil for ED, in order to obtain preliminary data on the cardiovascular effects of sildenafil depending on PDE5 genotypes; 15 of these patients were also affected by EH (13 in pharmacological treatment, five in monotherapy), in wash-out on the day of the study. Height (without shoes), weight (with light garments), systolic and diastolic BP in the supine and standing positions (SBP and DBP, mean of three measurements with mercury sphygmomanometer) and HR were taken by a physician. After baseline measurements, 50 mg of sildenafil was orally administered and BP and HR measurements were repeated at 30 and 90 min; then, blood was drawn for genomic DNA extraction and genotyping.
Genetic evaluation
Genomic DNA was extracted from blood samples with a commercially available DNA extraction kit (QIAamp DNA Blood Midi kit, QIAGEN, Hilden, Germany).
We analyzed the published sequence of PDE5A 5 0 -flanking region 23 (AB001615) and amplified by PCR a functionally relevant region ( Figure 1 ) that contains two binding sites (AP1 element) for the AP1 complex, a cGMP-responsive regulatory element activated through phosphorylation by cGMPdependent protein kinase I and II (G-kinase). 25 PCR was carried out in a total volume of 25 ml, from 40 ng of genomic DNA, 50 ng of each primer (upstream 5 0 -TTGCTTTTCTTTGGTTGTGGCT-3 0 and downstream 5 0 -GTGTCATCCTTTGCTTTGTCTG-3 0 ) and using the 'Ready to Go' PCR kit (Amersham Pharmacia Biotech, Milan, Italy). A total of 35 cycles of amplification were performed, consisting of denaturation at 961C for 50 s, annealing at 621C for 50 s and elongation at 721C for 1 min. An initial denaturation step was carried out at 971C for 5 min and a final elongation was carried out at 721C for Sildenafil and PDE5 alleles F Salvi et al 10 min. These amplifications were carried out using the DNA Thermal Cycler (Perkin Elmer Cetus). The PCR products were analyzed by gel electrophoresis using 2% Seakem LE agarose (BioWhittaker Molecular Applications, Rockland, ME, USA). PCR products were then purified by agarose gel electrophoresis and eluted using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). Cycle sequencing (961C for 10 s, 501C for 5 s, 601C for 4 min, for 25 cycles) was carried out on both strands using the DNA sequencing kit Big Dye terminator Cycle sequencing Ready Reaction kit (Applied Biosystems, Warrington, UK) and the thermal cycler PCR Sprint (Hybaid). The reactions were purified by Centri-Sep Spin Columns (ABI PRISM, Applied Biosystems, Foster City, CA, USA), dried, and resuspended in TSR buffer (ABI PRISM, Applied Biosystems) and subjected to automated capillary sequencing (ABI PRISM 310 Genetic Analyzer, Applied Biosystems). Sequences were analyzed on electropherograms with Sequencing Analysis (ABI PRISM 3.3 Software, Applied Biosystems) and Sequence Navigator f (Applied Biosystems) software for Macintosh.
Genotyping of patients of steps 2 and 3 was carried out by PCR as above and enzymatic digestion with AluI. Digestion fragments were analyzed by gel electrophoresis using 3% NuSieve agarose (FMC BioProducts, Rockland, ME, USA).
Statistical analysis
Comparison of the allele and genotype frequency between groups (hypertensive patients with or without ED) was performed by w 2 test. The effect of sildenafil administration on BP and HR among baseline measurements and values at 30 and 90 min in the 21 patients studied at step 3 was evaluated by analysis of variance (adjusted for age, BMI and number of antihypertensive drugs) for repeated measurements.
Moreover, analysis of variance adjusted for age, BMI and number of antihypertensive drugs was used also to analyze the PDE5A alleles effect on basal SBP, DBP and HR in the supine and standing positions, and on BP and HR response to sildenafil, considering only two groups (homozygous TT vs TG þ GG grouped, considering the T allele as recessive), because of the small number of GG and TG genotypes.
Results
Analysis of sequences obtained from the first 10 patients with EH and idiopathic ED showed a T/G polymorphism (two homozygous GG, four heterozygous TG and four homozygous TT) at position À1142, near the AP1 regulatory elements (Figure 2 ) of the 5 0 -flanking region of the PDE5A gene. Restriction mapping revealed that the novel G(À1142) allele we identified lost the unique AluI site in the amplified DNA region, making it possible to identify the G(À1142) and T(À1142) alleles by digestion analysis of the 399 bp PCR product with AluI, as shown in Figure 3 . Thus, the frequency of G(À1142)T polymorphism was evaluated in 83 consecutive male hypertensive patients: the genotypes were 32 TT (38.6%), 39 TG (47%) and 12 GG (14.4%); the G(À1142) allele was 38% of the total alleles.
After medical interview, 50 of the 83 genotyped EH patients were excluded because of diabetes, treatment with diuretics, b-blockers and/or a 2 -agonists, or refused to answer. A total of 23 claimed not to suffer from ED (six TT, 16 TG and only one GG), whereas 10 patients reported ED (four TT, five TG and only one GG): the G(À1142) allele frequency between hypertensives without ED (n ¼ 23) and hypertensives with ED (n ¼ 10 þ 10) was similar (39.1 vs 37.5%, P ¼ 0.9), as was the genotypes distribution (P ¼ 0.22).
The clinical characteristics of 21 men with ED studied in the third step is shown in Table 1 . The administration of sildenafil 50 mg caused a mean decrease of 8.4 and 8.3 mmHg for SBP and 3.7 and 2.6 mmHg for DBP (in the supine and standing positions, respectively), values that were significantly different from baseline (Table 2) , except for standing DBP. No significant effects were found on Sildenafil and PDE5 alleles F Salvi et al HR (mean increase of 0.7 and 1.1 bpm, in the supine and standing positions, respectively). Genotypes were 14 TT (67%), three TG (14%) and four GG (19%), G allele 26%. After subdivision by genotype, no significant difference in BP variations was found between the two groups (homozygous TT vs TG/GG, T-recessive hypothesis of inheritance, because of the small number of GG and TG genotypes), both for values at baseline and for differences (DBP) between 0-30 and 0-90 min measures (Table 3) .
Discussion
We hypothesized a common genetic predisposition for the association between EH and ED. Our approach was to study a likely candidate gene for the intermediate phenotype EH/ED. In an interesting region of PDE5A promoter, we detected a novel polymorphism, T(À1142)G, embedded within the transcriptional regulatory AP1 element, sensible to cGMP. 23 The G allele we found is less frequent than the T allele, already described in literature, but all were similarly present both in hypertensive patients with ED and hypertensives without ED, without any difference in allele frequency between groups.
While this work was in progress, several studies were published about organization and function of the PDE5A gene promoter: [26] [27] [28] [29] the three isoforms of PDE5 (PDE5A1, 2 and 3), which differ only in the 5 0 ends of their mRNAs, are codified by three alternative first exons (arranged in the order A1-A3-A2). Transcription of these exons is regulated by two promoters: an intronic promoter for the PDE5A2 isoform and a more classical promoter in the 5 0 -flanking region for the other two isoforms. 26, 27 Analysis of this classic promoter shows that it is composed of a core promoter of 139 bp, an upstream regulatory region of 308 bp (containing AP2 and Sp1 elements) and a downstream regulatory region of 156 bp (containing several Sp1 elements). The entire promoter region ranges from 3115 to 3717 nucleotides (GenBank accession no. AF319172), from 86 bp upstream the initial ATG codon to more than 500 bp downstream the G(À1142)T polymorphism we identified. 27 Thus, it is possible that our polymorphism is not functional.
This first approach to this relevant intermediate phenotype failed to find an association between PDE5 alleles and EH/ED. It is important to consider that it is extremely difficult even to attempt to obtain reliable information on family history for ED; indeed, the subjects studied in steps 1 and 2 had positive family history for EH, but unknown family history for ED.
The administration of sildenafil 50 mg in our patients produced a reduction of BP similar to that described in literature in normal subjects and hypertensive patients taking medications, 30, 31 and had no effects on HR (Table 2) . Our data showed no correlations between G(À1142)T polymorphism and BP response to sildenafil; the high variability of the individual response to sildenafil, both in timing of maximal response and quantitative difference (Table 3) , may have contributed to the lack of significance.
Limitations of the study are the small sample of patients tested with oral sildenafil and the lack of the evaluation of the erectile response to sildenafil, which might be different on the basis of the PDE5 genotype.
On the basis of this first study in this field, we believe that a larger and/or more selected population, prolonged pharmacological wash-out and ambulatory BP monitoring might be used to better define the response profile for each hypertensive patient. Moreover, it is very interesting to proceed further in the study of PDE5A gene sequences in these patients to find functional mutations or polymorphisms.
Further studies are necessary to define the role, if any, of the T(À1142)G polymorphism and those of other yet unidentified alleles, in the attempt to define the genetic predisposition for EH with ED.
